RNA polymerase I is not translocated upon TBEV infection. by Martin Selinger (3195987)

Evaluation of the antimicrobial capacity of the films.^b'*' by Romina L. Abarca (12225493)

Evaluation of the biodegradability percentage of the films.^b'*' by Romina L. Abarca (12225493)

Determination of thickness of the films.^b'***' by Romina L. Abarca (12225493)

Analysis of color and opacity of elaborated films.^b'**' by Romina L. Abarca (12225493)

An observer’s steady- and pulsed-pedestal threshold data and model fits: (1) steady-pedestal paradigm (MC pathway) non-flicker adaptation condition (open circle); (2) steady-pedest... by Xiaohua Zhuang (11890694)

PCAIs inhibit NCI-H23 cell line viability. by Matthew D. Gregory (19929096)

RNLS is present in spindle-shaped cells in human chronic pancreatitis. by Yasheen Gao (6090842)

Determination of the minimum inhibitory concentration of the nisin/Na-EDTA mixture against <i>E</i>. <i>coli</i>.^b'*' by Romina L. Abarca (12225493)

A chromatogram of cultured HeLa cells via using the optimised HPLC method. by Hyo Jeong Kim (7490237)

Covid Mzt. by Francisco Flores-de-Santiago (20391063)

“…Canonical analysis of principal coordinates during the lockdown year revealed two key patterns: (1) sewage and harbor areas displayed a significant decrease in CHLA levels alongside elevated TSMC2, while (2) mangrove forest exhibited markedly reduced CDOM in post-pandemic years. …”

Effect of costunolide and BIBR1532 on AFP secretion by HepG2/C3A and PLC/PRF/5 cell lines. by Roula Tahtouh (714734)

“…The supernatant was then collected for ELISA. (A) Costunolide (5–50 μM) significantly decreased AFP production in a dose-dependent manner in the supernatants of HepG2/C3A cells after 48 h of treatment, whereas 50 μM costunolide decreased the AFP levels in the supernatant of PLC/PRF/5 cells. …”

Synergistic N/Mn Codoping Deagglomerate Carbon Coating of LiFePO₄/C To Boost Electrochemical Performance by Yu-Wei Wang (1749115)

“…Consequently, this strategy effectively improves the rate capability (119 mA h g^–1 at 10 C) while maintaining excellent cycling performance (88% capacity retention over 600 cycles at 5 C). …”

Image_1_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Image_3_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Image_2_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Diagnostic accuracy of antigen-based RDT kits for COVID-19 diagnosis/screening compared to PCR test for combined participants. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antigen-based RDT kits for COVID-19 diagnosis/screening compared to PCR test for asymptomatic participants. by Akhere A. Omonkhua (9727333)

Evaluation process for the validation of SARS-COV-2 rapid diagnostic tests in Nigeria. by Akhere A. Omonkhua (9727333)

Sociodemographic characteristics of participants (N = 1310). by Akhere A. Omonkhua (9727333)